Therefore, we investigated whether serum metabolites of Trp and IDO/TDO activity could serve as biomarkers for assessing smell/taste impairment (dysosmia/dysgeusia) in patients during the acute phase of COVID-19.<h4>Methods</h4>We conducted a retrospective case-control study. This evidence concerns the gene IDO1 and COVID-19.